Ataxia with oculomotor apraxia type 2 (AOA2), also called ataxia telangiectasia-like disorder (ATLD), is an autosomal recessive cerebellar ataxia caused by biallelic mutations in the SETX (Senataxin) gene. It is characterized by progressive cerebellar ataxia, oculomotor apraxia, elevated alpha-fetoprotein (AFP), and hypersensitivity to ionizing radiation — features overlapping with ataxia-telangiectasia (A-T) but without telangiectasias. [1][2]
AOA2 typically presents in adolescence (mean age 10-15 years) with progressive gait and limb ataxia, eventually leading to wheelchair dependence by the third or fourth decade. The disease is relatively common among autosomal recessive ataxias, particularly in populations with higher rates of consanguinity.
The SETX gene (senataxin) on chromosome 9q34 encodes a 2,673-amino-acid DNA/RNA helicase protein belonging to the superfamily 2 (SF2) helicase family. SETX is a nuclear protein with a putative NLS (nuclear localization signal) and a C-terminal helicase domain with ATPase activity. It functions in transcription, DNA repair, and RNA processing. [2:1]
SETX is named for its role in resolving R-loops (three-stranded structures formed during transcription when the nascent RNA anneals to the template DNA, displacing the non-template strand). R-loop accumulation causes transcription-replication conflicts and genomic instability.
Over 100 pathogenic variants have been identified in SETX, distributed across the gene: [3][4]
Most mutations are compound heterozygous (two different pathogenic variants), though some cases have homozygous mutations in consanguineous families.
SETX mutations disrupt multiple cellular processes: [5][2:2]
AOA2 follows a slowly progressive course: [3:1]
| Finding | AOA2 | Ataxia-Telangiectasia |
|---|---|---|
| Serum AFP | Elevated | Elevated |
| Telangiectasias | Absent | Present |
| Immunoglobulins | Normal | Often reduced |
| Radiosensitivity | Minimal | Marked |
| Chromosome breaks | Normal | Increased |
| Cancer risk | Lower than A-T | High |
Ataxias with oculomotor apraxia: an update. Advances in Experimental Medicine and Biology. 2012. ↩︎
Senataxin, a novel helicase at the interface of RNA processing and neurodegeneration. Advances in Experimental Medicine and Biology. 2013. ↩︎ ↩︎ ↩︎
AOA2: phenotypic diversity and mutation profile in 95 patients. Neurology. 2016. ↩︎ ↩︎
Ataxia with oculomotor apraxia type 2: advances and caveats. Current Neurology and Neuroscience Reports. 2013. ↩︎
Molecular mechanisms of senataxin in neurodegeneration and cancer. Frontiers in Molecular Neuroscience. 2020. ↩︎ ↩︎